Ocugen Inc (NASDAQ: OCGN) is a clinical-stage biopharmaceutical company developing gene therapies, biologics, and cell therapies for ophthalmic and other diseases. The company generates no product revenue as of FY2025, recording only collaborative arrangement revenue on its income statement while operating at a net loss. Ocugen's pipeline includes OCU410ST, a subretinal gene therapy in a Phase 2/3 pivotal confirmatory trial (GARDian3) for Stargardt disease, with a masked interim analysis planned for mid-2026; OCU200, a recombinant fusion protein of tumstatin and transferrin in Phase 1 for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration, with first patient dosed in January 2025; and NeoCart, a Phase 3-ready autologous chondrocyte-derived neocartilage implant for knee cartilage repair in adults. The company has completed renovation of a GMP facility to support NeoCart clinical study and initial commercial launch. Ocugen is headquartered in the United States and carries no disclosed product revenue base, funded instead through equity and collaborative arrangements.

Revenue model

Ocugen earns collaborative arrangement revenue, which constitutes its only disclosed revenue line as of FY2025. The company has no approved commercial products and does not generate product sales revenue. Operations are funded through equity financing and partnership arrangements.

Products and services

OCU410ST: subretinal gene therapy for Stargardt disease, Phase 2/3 (GARDian3 trial); interim analysis planned mid-2026. OCU200: recombinant fusion protein (tumstatin plus transferrin) for DME, DR, and wet AMD, Phase 1 initiated January 2025. NeoCart: autologous chondrocyte-derived neocartilage implant for knee cartilage repair, Phase 3-ready. Novel inhaled mucosal vaccine platform for COVID-19 and seasonal influenza, in development.

Customers and end markets

End markets are ophthalmology (retinal diseases including Stargardt disease, diabetic macular edema, diabetic retinopathy, wet age-related macular degeneration) and orthopedics (knee cartilage repair in adults). As a clinical-stage company with no approved products as of FY2025, Ocugen has no commercial customers.

Value-chain role

Ocugen operates as a drug developer and manufacturer. It conducts clinical trials, manages regulatory submissions, and has built a GMP manufacturing facility to produce patient-specific NeoCart implants. The company relies on third-party collaborators, contractors, and service providers for certain clinical and operational functions.

Geographic exposure

Ocugen is headquartered in the United States. Clinical trials are conducted at multiple centers. No specific geographic revenue breakdown is disclosed in the FY2025 filing excerpts.

Source: SEC 10-K, filed 2026-03-04

Industry: Biological Products, (No Diagnostic Substances) Peers: Heron Therapeutics Inc Jade Biosciences Inc ALX Oncology Holdings Inc bluebird bio, Inc. Celularity Inc Cytodyn Inc EAGLE PHARMACEUTICALS, INC. Kodiak Sciences Inc MeiraGTx Holdings PLC